Cognition Therapeutics (CGTX): Price and Financial Metrics


Cognition Therapeutics (CGTX): $2.68

0.19 (+7.63%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CGTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CGTX Stock Price Chart Interactive Chart >

Price chart for CGTX

CGTX Price/Volume Stats

Current price $2.68 52-week high $13.80
Prev. close $2.49 52-week low $2.31
Day low $2.50 Volume 36,700
Day high $2.79 Avg. volume 72,940
50-day MA $2.89 Dividend yield N/A
200-day MA $0.00 Market Cap 60.56M

Cognition Therapeutics (CGTX) Company Bio


Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in phase 2 clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed phase 1 clinical trial to treat early-stage Alzheimer's disease; and in preclinical trial to treat dementia with Lewy bodies (DLB) and dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.


CGTX Latest News Stream


Event/Time News Detail
Loading, please wait...

CGTX Latest Social Stream


Loading social stream, please wait...

View Full CGTX Social Stream

Latest CGTX News From Around the Web

Below are the latest news stories about Cognition Therapeutics Inc that investors may wish to consider to help them evaluate CGTX as an investment opportunity.

Cognition Therapeutics to Participate in Panel during the BIO CEO & Investor Conference on the Development of Neurodegenerative Therapeutics

Anthony Caggiano, M.D., Ph.D., Participating on February 15th Panel: “Exploring the Possibilities of Developing Neurodegenerative Therapeutics”PURCHASE, N.Y., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat age-related degenerative diseases, today announced that Anthony Caggiano, M.D., Ph.D., chief medical officer and head of R&D, will participate in a panel discussion during the annual BIO CEO & Inv

Yahoo | February 8, 2022

CGTX stock gains as company highlights upcoming milestones with Alzheimers in focus

Cognition Therapeutics (CGTX) has added ~8.3% on below-average volume after the company announced its clinical milestones for 2022.During the year, Purchase, New York-based

Seeking Alpha | January 11, 2022

Cognition Therapeutics Provides Update on Corporate and Pipeline Progress and Reviews Goals for 2022

PURCHASE, N.Y., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the “Company” or “Cognition”), today provided a summary of the Company’s 2021 accomplishments and outlined upcoming milestones anticipated in the year ahead. Key 2021 Financial A

Yahoo | January 10, 2022

Companies Like Cognition Therapeutics (NASDAQ:CGTX) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Yahoo | January 8, 2022

Cognition Therapeutics Receives Grant from Michael J. Fox Foundation to Support Development of Sigma-2 Receptor Modulator for Parkinson’s Disease

NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage neuroscience company developing drugs that treat age-related degenerative diseases, today announced that the company has been awarded a Therapeutic Pipeline Program Grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF). This grant will fund preclinical studies of two sigma-2 (σ-2) receptor modulators in animal models of Parkinson’s disease that will be led by Cognition The

Yahoo | January 4, 2022

Read More 'CGTX' Stories Here

CGTX Price Returns

1-mo -6.94%
3-mo -7.59%
6-mo -67.59%
1-year N/A
3-year N/A
5-year N/A
YTD -57.59%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6526 seconds.